Description du projet DEENESFRITPL Un vaccin de nouvelle génération contre la maladie à pneumocoque La maladie à pneumocoque entraîne la mort d’environ 200 000 personnes chaque année, rien qu’en Europe. Les vaccins actuels sont onéreux, et les pays en développement ne peuvent pas se permettre d’offrir la protection nécessaire à leurs citoyens. Dans le même temps, la résistance aux antibiotiques et l’adaptation de Streptococcus pneumoniae réduisent encore davantage l’efficacité des vaccins antipneumococciques. La société britannique Immunobiology Ltd. a développé un vaccin antipneumococcique innovant, appelé PnuBioVax™, qui offre une protection contre toutes les souches pneumococciques, et s’avère sûr dans son utilisation. Dans le cadre du projet PnuBioVax, financé par l’UE, une étude de faisabilité a été réalisée ainsi qu’une analyse complète du potentiel technique et commercial de ce nouveau vaccin. En plus de son faible coût de fabrication, PnuBioVax™ peut devenir un vaccin de premier choix pour les pays en développement, contribuant ainsi à la lutte mondiale contre la maladie à pneumocoque. Afficher les objectifs du projet Masquer les objectifs du projet Objectif Pneumococcal disease, caused by the pathogenic bacteria Streptococcus pneumoniae, is a major cause of mortality in the young and elderly. In Europe, it is responsible for 230,000 annual deaths and an economic burden of € 10B annually. Due to the high cost of the current vaccines, rates of infant disease and death are even higher in developing countries, accounting for 1.6M deaths per year. The introduction of pneumococcal vaccines in Europe over the 20th century was pivotal in the reduction of pneumococcal pneumonia cases by 31%. Despite these good results, vaccine efficiency is now decreasing due to the adaptation of S. pneumoniae to the existing vaccines, but also due to its growing antibiotic resistance.ImmunoBiology’s (ImmBio) platform technology has been used to create a pneumococcal vaccine called PnuBioVax™ (PBV) that aims to address the burden of the disease by offering protection against 100% of the pneumococcal strains. As a result of low manufacturing costs (<€ 1), PBV could become a game changer in the combat of the disease, facilitating its adoption in developing countries. The manufacturing cost of PBV represents a reduction of >95% compared to PCV13, the market leader, estimated at € 20. The vaccine has already been tested in humans, demonstrating its safety and effectiveness.ImmBio is an innovative company, established in 1999 in the UK, which develops state-of-the-art vaccines using the ImmBioVax™ (IBV) vaccine platform technology. To date, ImmBio has raised circa € 10M in grants and awards. These funds, allowed the company to take the IBV technology from concept to clinical readiness products. The proposed work in Phase 1 of the SME instrument fits into their overall plan to reach the market by contributing to the financial resources needed to complete PBV’ clinical studies and ensure market uptake. Champ scientifique medical and health sciencesclinical medicinepneumologymedical and health scienceshealth sciencesinfectious diseasesmedical and health sciencesbasic medicineimmunologymedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccinesmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme H2020-EU.3. - PRIORITY 'Societal challenges H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies Thème(s) EIC-SMEInst-2018-2020 - SME instrument Appel à propositions H2020-EIC-SMEInst-2018-2020 Voir d’autres projets de cet appel Sous appel H2020-SMEInst-2018-2020-1 Régime de financement SME-1 - SME instrument phase 1 Coordinateur IMMUNOBIOLOGY LIMITED Contribution nette de l'UE € 50 000,00 Adresse BABRAHAM RESEARCH CAMPUS BUILDING 260 CB22 3AT CAMBRIDGE Royaume-Uni Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région East of England East Anglia Cambridgeshire CC Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
